# ATLAS (NCT03991403)

> Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03991403
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Samsung Medical Center
- Conditions: Non-small Cell Lung Cancer
- Interventions: Atezolizumab(Tecentriq); Pemetrexed; Bevacizumab; Carboplatin; Paclitaxel; Carboplatin or cisplatin
- Enrollment: 228
- Primary outcome: progression-free survival, PFS

## Indexed commentary on ATLAS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=atlas-nct03991403